Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - Motzer, RJ; Russo, P; Grünwald, V (The Lancet, 2023)